Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.

PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutations can help predict the antitumor activity of phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway inhibitors in both preclinical and clinical settings. In light of the recent discovery of tumor-init...

Full description

Bibliographic Details
Main Authors: Douglas D Fang, Cathy C Zhang, Yin Gu, Jitesh P Jani, Joan Cao, Konstantinos Tsaparikos, Jing Yuan, Melissa Thiel, Amy Jackson-Fisher, Qing Zong, Patrick B Lappin, Tomoko Hayashi, Richard B Schwab, Anthony Wong, Annette John-Baptiste, Shubha Bagrodia, Geritt Los, Steve Bender, James Christensen, Todd Vanarsdale
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3695076?pdf=render

Similar Items

Similar Items